BOSTON SCIENTIFIC BUYS LEADERSHIP POSITION IN INTERVENTIONAL NEURORADIOLOGY WITH $1.1 BIL. TARGET MERGER; STOCK DEAL RESOLVES COMPANIES' PATENT DISPUTE
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's $1.1 bil. merger agreement with Target Therapeutics puts the interventional neuroradiology segment firmly in the hands of large, diversified medical products firms.
You may also be interested in...
Essure Permanent Birth Control Will Become Standard Of Care – Conceptus
Conceptus expects its Essure non-incisional permanent birth control device to replace tubal ligation for the estimated 700,000 women undergoing sterilization procedures in the U.S. annually
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.